Casper H J van Eijck Selected Research

folfirinox

3/2022	Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program.
3/2022	Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment.
1/2022	FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
1/2022	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
1/2022	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
12/2021	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
12/2021	Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
10/2021	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
1/2021	Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.
6/2020	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Casper H J van Eijck Research Topics

Disease

55	Neoplasms (Cancer) 03/2022 - 12/2002
46	Pancreatic Neoplasms (Pancreatic Cancer) 10/2022 - 01/2005
19	Adenocarcinoma 01/2022 - 08/2007
11	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2002
8	Pancreatic Fistula (Pancreatic Fistulas) 07/2022 - 03/2016
8	Neuroendocrine Tumors (Neuroendocrine Tumor) 05/2021 - 12/2002
6	Pancreatitis 10/2021 - 04/2006
6	Carcinoma (Carcinomatosis) 01/2016 - 11/2004
3	Pain (Aches) 03/2022 - 04/2012
3	Fibrosis (Cirrhosis) 06/2021 - 01/2005
3	Primitive Neuroectodermal Tumors (PNET) 05/2021 - 03/2016
3	Lymphatic Metastasis 01/2021 - 03/2016
3	Cholangitis 01/2020 - 04/2012
3	Gastric Outlet Obstruction 07/2011 - 06/2007
3	Wounds and Injuries (Trauma) 09/2006 - 03/2003
2	Hemorrhage 01/2022 - 01/2020
2	Rectal Neoplasms (Rectal Cancer) 01/2022 - 03/2016
2	Necrosis 10/2021 - 01/2005
2	Chronic Pancreatitis 01/2020 - 04/2012
2	Primary Hyperparathyroidism 01/2016 - 01/2012
2	Neoplasm Micrometastasis 09/2009 - 04/2003
1	Fistula 07/2022
1	Clinical Deterioration 03/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Colonic Neoplasms (Colon Cancer) 01/2022
1	Wound Infection (Wound Infections) 01/2022
1	Genomic Instability 12/2021
1	COVID-19 06/2021
1	Pre-Eclampsia (Preeclampsia) 01/2021
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021

Drug/Important Bio-Agent (IBA)

13	folfirinoxIBA 03/2022 - 11/2018
9	Somatostatin Receptors (Somatostatin Receptor)IBA 08/2017 - 12/2002
7	Peptide Receptors (Peptide Receptor)IBA 01/2022 - 12/2002
6	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 01/2005
6	Radioisotopes (Radionuclides)IBA 01/2022 - 12/2002
6	Biomarkers (Surrogate Marker)IBA 06/2021 - 01/2019
6	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2016 - 04/2003
5	Gemcitabine FDA Link 10/2022 - 04/2019
5	Leucovorin (Folinic Acid)FDA Link 01/2022 - 12/2008
5	Interferon Type IIBA 03/2021 - 11/2006
5	ParaffinIBA 01/2021 - 12/2010
5	Octreotide (Sandostatin)FDA LinkGeneric 05/2014 - 12/2002
4	Biological ProductsIBA 01/2022 - 01/2005
4	MicroRNAs (MicroRNA)IBA 10/2021 - 11/2019
4	BilirubinIBA 12/2020 - 01/2010
4	Pentetic Acid (DTPA)FDA LinkGeneric 05/2014 - 04/2003
4	Tyr(3)- octreotateIBA 03/2010 - 04/2003
4	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 03/2010 - 04/2003
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 01/2020
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2020
3	Peptides (Polypeptides)IBA 01/2016 - 05/2010
3	3-Tyr-octreotideIBA 03/2010 - 04/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2006 - 12/2004
3	CytokinesIBA 09/2006 - 12/2004
2	poly(I).poly(c12,U) (ampligen)IBA 03/2022 - 06/2021
2	Carcinoembryonic AntigenIBA 01/2021 - 06/2015
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2021
2	CalciumIBA 08/2020 - 01/2012
2	130-nm albumin-bound paclitaxelIBA 06/2020 - 04/2019
2	C-Reactive ProteinIBA 01/2020 - 01/2016
2	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2015 - 03/2014
2	InterferonsIBA 05/2011 - 11/2006
2	pentetreotide (OctreoScan)FDA Link 05/2010 - 04/2003
2	yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acidIBA 03/2010 - 03/2010
2	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2007 - 04/2007
2	Interleukin-6 (Interleukin 6)IBA 09/2006 - 05/2006
1	Valproic Acid (Depakote)FDA LinkGeneric 02/2022
1	Histone Deacetylase InhibitorsIBA 02/2022
1	lutetium Lu 177 dotatateIBA 01/2022
1	Amylases FDA Link 11/2021
1	Messenger RNA (mRNA)IBA 06/2021
1	Toll-Like Receptor 3IBA 06/2021
1	Antiviral Agents (Antivirals)IBA 06/2021
1	CarbohydratesIBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	CA-19-9 Antigen (CA 19-9 Antigen)IBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Circulating Tumor DNAIBA 01/2021

Therapy/Procedure

30	Therapeutics 01/2022 - 12/2002
20	Drug Therapy (Chemotherapy) 03/2022 - 01/2005
13	Pancreaticoduodenectomy 07/2022 - 11/2004
11	Radiotherapy 01/2022 - 01/2005
8	Chemoradiotherapy 10/2022 - 01/2005
6	Neoadjuvant Therapy 10/2022 - 01/2005
5	Pancreatectomy 01/2021 - 03/2003
4	Immunotherapy 03/2021 - 01/2015
4	Palliative Care (Palliative Therapy) 01/2015 - 06/2007
3	Catheters 10/2021 - 01/2017
3	Laparotomy 08/2017 - 04/2006
3	Stents 04/2012 - 06/2007
3	Gastric Bypass (Roux-en-Y Gastric Bypass) 07/2011 - 06/2007
2	Length of Stay 01/2022 - 01/2016
2	Adjuvant Chemotherapy 12/2020 - 01/2020
2	Conservative Treatment 01/2020 - 01/2016
2	Sphincterotomy 01/2020 - 01/2016
2	Operative Surgical Procedures 03/2016 - 11/2004
2	Aftercare (After-Treatment) 01/2005 - 04/2003
1	Immunomodulation 03/2022
1	Patient Readmission 01/2022